Antibody-based immunotherapies for Parkinsonian syndromes

作     者：Lars Tonges Maria Angela Samis Zella 

作者机构：Department of NeurologySt. Josef-HospitalRuhr-University BochumBochumGermany Neurodegeneration ResearchProtein Research Unit Ruhr (PURE)Ruhr University BochumBochumGermany Department of NeurologySt. Josef-HospitalKatholische Kliniken RuhrhalbinselContilia GruppeEssenGermany 

出 版 物：《Neural Regeneration Research》 (中国神经再生研究（英文版）)

年 卷 期：2019年第14卷第11期

页      面：1903-1904页

核心收录：

学科分类：0710[理学-生物学] 1001[医学-基础医学(可授医学、理学学位)] 10[医学] 

主　　题：Parkinsonian syndromes Parkinson’s disease(PD) multiple system atrophy(MSA) 

摘      要：What is the rationale for immunotherapies in Parkinsonian syndromes (PS)? PS are neurodegenerative diseases which are clinically characterized by a hypokinetic phenotype in combination with additional motor and non-motor symptoms. One major pathological hallmark of all PS consists of a non-physiological detrimental accumulation of protein aggregates which appear intracellularly in neurons and glial cells but also in the extracellular space (Wong and Krainc, 2017). Depending on the pathogenic protein, PS can be divided into synucleinopathies, characterized by aggregation of the protein alpha-Synuclein (aSyn), and tauopathies, characterized by aggregation of the protein Tau (Levin et al., 2016;Poewe et al., 2017). Clinical syndromes of synucleinopathies include Parkinson’s disease (PD), multiple system atrophy (MSA) and dementia with Lewy bodies, and tauopathies include progressive supranuclear palsy (PSP) and corticobasal degeneration.